MIP and leprosy: A vaccine against leprosy based on MIP is approved for human use, where it has resulted in modest clinical improvement, accelerated bacillary clearance, and increased immune responses to Mycobacterium leprae antigens, thereby shortening the full recovery time of the patients [2], [3], [4].